Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations

Soraya L. Moghazeh, Xi Pan, Taraq Arain, C. Kendall Stover, James M. Musser, Barry N. Kreiswirth

Research output: Contribution to journalArticle

107 Scopus citations

Abstract

A collection of 24 rifampin-resistant clinical isolates of Mycobacterium tuberculosis with characterized RNA polymerase β-subunit (rpoB) gene mutations was tested against the antimycobacterial agents rifampin, rifapentine, and KRM-1648 to correlate levels of resistance with specific rpoB genotypes. The results indicate that KRM-1648 is more active in vitro than rifampin and rifapentine, and its ability to overcome rifampin resistance in strains with four different genetic alterations may prove to be useful in understanding structure-function relationships.

Original languageEnglish (US)
Pages (from-to)2655-2657
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume40
Issue number11
DOIs
StatePublished - Nov 1996

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations'. Together they form a unique fingerprint.

Cite this